FindTrial
Sign In

The application of Truscreen for cervical cancer screening

Contrast study of Truscreen compare with cervial cellular smear, VIA, VILI, colposcope or HR-HPV DNA test for cervial cancer screening

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDT-12002074
Enrollment
Unknown
Registered
2012-03-24
Start date
2009-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervial cancer screening

Interventions

Gold Standard:
Index test:

Sponsors

Lina HU
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women who were between 20 to 65 years of age and were willing and able to sign the informed consent were offered participation. They must had one year or more sexual life.

Exclusion criteria

Exclusion criteria: Exclusion criteria for the study were current menstrual period, current or recent pregnancy (<4 months post delivery), previous total hysterectomy, and surgical treatment to the cervix within the previous 3 months.

Design outcomes

Primary

MeasureTime frame
sensitivity of Truscreen;speci?city of Truscree;—

Countries

China

Contacts

Public ContactPei YANG
568708096@qq.com+86 18981775159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026